These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8913395)

  • 1. Preserve the FDA's authority.
    Guharoy R
    Am J Health Syst Pharm; 1996 Nov; 53(21):2636, 2638. PubMed ID: 8913395
    [No Abstract]   [Full Text] [Related]  

  • 2. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
    Joffe S; Lynch HF
    N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 4. Reviving the FDA's Authority to Publicly Explain Why New Drug Applications Are Approved or Rejected.
    Herder M
    JAMA Intern Med; 2018 Aug; 178(8):1013-1014. PubMed ID: 29971404
    [No Abstract]   [Full Text] [Related]  

  • 5. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.
    Farrell AT; Goldberg KB; Pazdur R
    Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876
    [No Abstract]   [Full Text] [Related]  

  • 6. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulation of drugs and devices: an evolution.
    Merrill RA
    Health Aff (Millwood); 1994; 13(3):47-69. PubMed ID: 7927161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 9. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 11. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 12. Checks and Balances on FDA's Authority.
    Lynch HF; Lurie P; Cohen IG
    JAMA; 2024 Sep; 332(9):705-706. PubMed ID: 38889181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women's health advocates dismayed at FDA's Plan B decision.
    Ready T
    Nat Med; 2005 Oct; 11(10):1016. PubMed ID: 16211017
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA's decision on Plan B: a surrogate for lack of commitment to women's health.
    Merkatz RB
    J Womens Health (Larchmt); 2005 Nov; 14(9):860. PubMed ID: 16313214
    [No Abstract]   [Full Text] [Related]  

  • 16. Bolstering the FDA's drug-safety authority.
    Schultz WB
    N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk management and intrusions on medical practice: striking a balance.
    Enzi MB; Kennedy EM
    Health Aff (Millwood); 2007; 26(3):678-80. PubMed ID: 17485743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advocates call for long-term extension of the FDA's rare pediatric disease priority review program: Federal voucher program considered instrumental in shortening drug review, approval period.
    Am J Med Genet A; 2017 Jan; 173(1):7-8. PubMed ID: 27991734
    [No Abstract]   [Full Text] [Related]  

  • 19. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
    MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M
    JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marketing drugs too early in testing.
    Begg CB; Brawley O; Califf RM; Demets DL; Ellenberg SS; Kaplan RS
    Science; 2006 Apr; 312(5771):195. PubMed ID: 16614197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.